Objective. To evaluate the effects of treatment with interleukin-1 receptor antagonist (IL-1Ra) on synovial tissue in rheumatoid arthritis (RA).
Rheumatoid arthritis (RA) is characterized by chronic synovial in¯ammation and progressive erosion of cartilage and bone w1x. A variety of cell populations in®ltrate the synovium and produce mediators capable of maintaining the in¯ammatory process and stimulating the production of destructive enzymes. Cytokine networks in¯uence events at both the local and the systemic level. It has been suggested that interleukin-1b (IL-1b) and tumour necrosis factor a (TNF-a) are pivotal proin¯ammatory cytokines w1, 2x. In experimental models, IL-1 increases cell migration into the in¯amed synovium by the up-regulation of adhesion molecules, stimulates the production of prostaglandins and metalloproteinases, inhibits collagen and proteoglycan synthesis and stimulates osteoclastic bone resorption w2, 3x. The physiological regulation of IL-1 is due to the presence of its naturally occurring inhibitor, interleukin-1 receptor antagonist (IL-1Ra) w2x. IL-1Ra is a speci®c competitive inhibitor of IL-1 and binds avidly to IL-1 receptors without activating the target cell. IL-1Ra is also produced mainly by synovial macrophages w4x. It is thought that dysregulation of IL-1Ra may be responsible for the predominance of IL-1 in RA w5x.
The therapeutic potential of IL-1Ra in in¯ammatory arthritis has been investigated in in vitro studies, animal models and in human RA. IL-1Ra inhibited both IL-1 and TNF-a-induced prostaglandin E 2 and collagenase production by human synoviocytes w6x. It inhibited neutrophil in®ltration and cartilage proteoglycan loss after intra-articular injection of IL-1 into rabbit knee joints w7x. A recent randomized controlled trial of IL-1Ra in patients with severe, active RA demonstrated signi®cant clinical improvements compared with placebo w8x. In addition, IL-1Ra caused a 41% reduction in the rate of progressive joint damage. In this study, we examined the in vivo effects of IL-1Ra on in¯amed synovial tissue. The reduction in mononuclear cell in®ltration, possibly mediated by the down-regulation of adhesion molecule expression, was striking after treatment with IL-1Ra at 150 mguday.
Methods

Patients
The patients included in this study had been recruited into one of two randomized clinical trials of recombinant human IL-1Ra in RA. In the ®rst trial, 472 patients entered one of four treatment groups: placebo and IL-1Ra at 30, 75 and 150 mguday by self-administered subcutaneous injection for 24 weeks w8x. In brief, patients aged 18±75 yr were eligible for inclusion in this study if they met the American College of Rheumatology criteria for the diagnosis of RA w9x, had symptoms of RA for more than 6 months and less than 8 yr, had clinical features of active disease and a C-reactive protein (CRP) concentration greater than 1.5 mgudl. In all, 11 patients were recruited to the multicentre study at St Vincent's University Hospital, Dublin, and 10 agreed to a needle biopsy of an affected knee joint immediately before starting treatment. Written consent was obtained from all who participated in this small substudy. A follow-up needle biopsy was undertaken in seven patients after 24 weeks and evaluable pretreatment and post-treatment synovial tissue was available in six patients. In a 24-week extension study, patients who had received placebo were randomized to one of the three IL-1Ra treatment groups for a further 24 weeks. One patient who had initially received placebo agreed to a third biopsy after 24 weeks in the extension study. In addition, pretreatment and post-treatment tissue samples obtained by arthroscopic biopsy of an affected knee were obtained at the same time-points from one patient attending the Karolinska Hospital, Stockholm, Sweden, and one patient attending Leiden University Hospital, Leiden, The Netherlands. All tissue samples were evaluated by Anti-CD3 and anti-CD68 were from Dakopatts (Copenhagen, Denmark), anti-VCAM-1, anti-ICAM-1 and anti-P-selectin were from Novocastra Laboratories (Newcastle Upon Tyne, UK) and anti-E-selectin was from R&D Systems (Oxford, UK). the same investigator (GC), who had no knowledge of the treatment, clinical course or radiological outcome. Radiographs of hands and wrist of each of these nine patients were obtained at weeks 0 and 24. They were reviewed and scored according to Larsen et al. w10x by two radiologists who were blinded both to the treatment group and the time of radiography. Approval of the study was obtained from the ethics committee of each participating institution.
In a second multicentre, dose-®nding, randomized clinical trial with similar entry criteria, 10 patients were recruited at St Vincent's University Hospital and received placebo, IL-1Ra 2.5, 10 or 30 mguday for 12 weeks. After the code had been broken, three patients were identi®ed from the two treatment groups relevant to the biopsy substudy (placebo and IL-1Ra 30 mguday) with evaluable pretreatment and post-treatment tissue samples. The tissues were evaluated by the same investigator (GC). In view of the shorter study duration, radiographic analysis was not included as an outcome measure.
Synovial biopsy and analysis of tissue
Needle biopsy of one clinically in¯amed knee was performed under sterile conditions as described previously w11x. The same location was chosen for the second biopsy. Multiple samples of synovial tissue were obtained from as wide an area as possible within reach of the needle. Arthroscopic biopsy was performed on two patients. The biopsy procedure was similar to needle biopsy, using a Stors 2.7 mm needle arthroscope.
The primary monoclonal antibody (mAb) clones used, their antigen and predominant cell speci®cities and the dilutions used are shown in Table 1 . A standard three-stage immunoperoxidase technique using serial sections was applied w11x. Only synovial sections in which the lining layer was clearly evident were included 
Results
Changes in mononuclear cell in®ltration Twelve paired synovial tissue samples, obtained before and after treatment, were available from 11 patients. One patient underwent needle biopsy before and after 24 weeks of treatment with placebo (Patient 1a; Table 2 ) and again after 24 weeks of treatment with IL-1Ra 150 mguday (Patient 1b; Table 2 ). In all, three patients had received placebo, six IL-1Ra 30 mguday and three IL-1Ra 150 mguday. All tissue samples demonstrated a high degree of intimal and subintimal mononuclear cell in®ltration before treatment (Table 2) . After treatment, patients receiving placebo demonstrated an 8±11% increase in the percentage of macrophages in the synovial intimal layer (Table 2 and Patients receiving placebo also demonstrated a 5±25% increase in subintimal macrophage in®ltration (Table 2) . Treatment with IL-1Ra 30 mguday had a variable effect on subintimal macrophage in®ltration ( q 19 to À 19% change). However, the three patients receiving IL-1Ra 150 mguday demonstrated a consistent and striking reduction in subintimal macrophage in®ltration (41±75%). Patients receiving placebo demonstrated a variable effect on subintimal lymphocyte in®ltration ( q 47 to À 53%) ( Table 2) . A variable effect was also observed after IL-1Ra 30 mguday ( q 97 to À 25%). IL-1Ra 150 mguday resulted in a consistent decrease in subintimal lymphocyte in®ltration, ranging from À 26 to À 97%. Figures 2 and 3 illustrate the changes in mononuclear cell in®ltration before and after placebo and after IL-1Ra 150 mguday (patient 1; Table 2 ). A variable effect on blood vessels was observed in all three groups (data not shown).
Changes in adhesion molecule expression Suf®cient tissue samples for the analysis of adhesion molecule expression were available from only six patients: one receiving placebo, four receiving IL-1Ra 30 mguday and one receiving IL-1Ra 150 mguday ( Table 3 ). The patient who had received IL-1Ra 150 mguday demonstrated a reduction (74%) in the expression of synovial membrane E-selectin, but not P-selectin, on vascular endothelial cells (Table 3 and Fig. 4) . In the ®ve patients receiving IL-1Ra 30 mguday or placebo, no convincing changes in E-selectin or P-selectin expression were observed. The patient receiving IL-1Ra 150 mguday also demonstrated a striking reduction in VCAM-1 expression on in®ltrating mononuclear cells in both the intimal (64%) and subintimal layers (26%) ( Table 3 and greater than 10% was observed in the subintimal layer in only one patient (Patient 4; Table 3 ).
Changes in the clinical course and radiological outcome
The clinical course, represented by CRP values, and the radiological outcome are documented in Table 4 . It is noteworthy that an inconsistent clinical response and considerable radiological progression was observed in patients receiving placebo. By comparison, a fall in CRP concentration was observed in eight of nine patients receiving IL-1Ra 30 or 150 mguday and an apparent arrest of radiological progression was observed in four of nine with serial radiological analysis. There was no correlation between the radiological outcome and changes in the CRP values. Correlations were sought between radiological outcome and changes in intimal macrophages and subintimal macrophages and T lymphocytes. The data highlighting the relationships between joint damage and changes in intimal layer macrophage in®ltration are shown in Fig. 6 . Thus, in the four patients demonstrating apparent arrest of joint damage (Patients 5, 7, 10 and 1b; Fig. 6 ) a consistent reduction in the percentage of intimal macrophages was observed, and all had received IL-1Ra. This contrasted with patients who demonstrated progressive joint damage (Patients 1a, 2, 4, 6 and 11; Fig. 6 ), which was associated with an increase in intimal macrophages in three. No statistical differences were observed between the two groups when changes in the subintimal populations of macrophages and T lymphocytes were examined.
Discussion
In this study, treatment of RA with IL-1Ra 150 mguday resulted in reduced numbers of intimal macrophages and subintimal macrophages and lymphocytes. Synovial biopsy and immunohistochemical evaluation have been employed previously in the study of the therapeutic response to conventional and biological agents w12±18x. In this and other multicentre studies of biological agents, the numbers recruited for immunohistological analysis have been unavoidably small w15, 16x, as relatively few participating centres have facilities for serial synovial biopsy. The small numbers precluded meaningful statistical analysis. Nevertheless, many of the immunohistological changes observed in therapeutic studies could be attributed directly or indirectly to phar-macological effects w15±18x. The method of histological analysis used in this study can identify small changes of biological relevance w19x. The validity of the method was augmented by the demonstration that quanti®cation of limited areas of synovial tissue (equivalent to only 1 mm 2 ) provided results which were similar to those obtained from the analysis of areas up to 6.7 mm 2 from the same joint w20x. The very low coef®cients of variation observed in this study (see Methods) further suggest that the small immunohistological changes observed in some patients represented biologically signi®cant in vivo effects.
The proliferating synovial intimal layer is composed of two distinct cell populations w21, 22x. In health the majority are ®broblast-like synoviocytes. In RA the majority are macrophages derived from monocyte q and they may also express both VCAM-1 and ICAM-1. Intimal macrophages are a major source of IL-1. Macrophages produce a number of other proin¯ammatory cytokines which have a central role in RA, including TNF-a and GM-CSF w20x. We have previously demonstrated signi®cant correlations between the numbers of both intimal and subintimal layer macrophages and the degree of articular damage in RA w11x. The present study provided an opportunity to further explore these relationships. The reduced intimal layer macrophage accumulation observed after IL-1Ra treatment may explain the apparent arrest of joint damage observed in four of nine patients treated for 24 weeks. Reduced macrophage accumulation may also be accompanied by inhibition of the IL-1-mediated production of tissuedegrading enzymes by macrophages and synoviocytes. Synoviocytes activated by IL-1 and other cytokines are the major source of tissue-degrading enzymes, including matrix metalloproteinases, serine proteases and cathepsins, which are believed to be the direct cause of cartilage damage. This study did not evaluate synovial ®broblasts and other cell populations, such as NK cells, dendritic cells and mast cells, which may also contribute to the pathogenesis of joint damage.
IL-1 up-regulates the expression of E-selectin, but not P-selectin, on vascular endothelium w23x. The effect of IL-1Ra 150 mguday on synovial tissue adhesion molecule expression could be evaluated in only one patient, but the selective down-regulation of E-selectin and not P-selectin that was observed suggests an in-vivo biological effect. The selectin family of adhesion molecules are responsible for the tethering of leukocytes to the vessel surface, permitting the rolling of the cell in the direction of¯ow. This phase occurs before the integrinmediated arrest of leukocyte motion, ®rm adhesion and transmigration. E-selectin and P-selectin are both expressed in RA synovial tissue, but only E-selectin expression is increased compared with non-in¯amed synovium w24x. Both E-selectin and P-selectin are involved in macrophage adhesion w23x. The reduction in macrophage in®ltration, despite the persistent expression of P-selectin, supports the suggestion that E-selectin is more important than P-selectin in mediating macrophage migration in in¯amed RA joints, as previously described in studies of neutrophil migration w17x. E-selectin is also involved in lymphocyte migration but P-selectin is not. VCAM-1 and ICAM-1 are more widely distributed in RA synovium and both are also up-regulated by IL-1 w23x. These are important molecules in cell-to-cell interactions, including macrophage± ®broblast and macrophage±lymphocyte interactions, and in regulating the migration of cells through synovial tissue into the synovial¯uid.
Studies of IL-1Ra treatment in experimental models of arthritis have consistently demonstrated relatively modest effects on clinical measures of joint in¯amma-tion w25±28x. However, the effects on inhibiting IL-1-mediated metalloproteinase release, proteoglycan breakdown and cartilage damage observed in the same animal models have been striking. Moreover, when the human IL-1Ra gene was transferred into the knee joints of rabbits with antigen-induced arthritis, a marked chondroprotective effect was observed in association with a limited anti-in¯ammatory effect w29x. Similarly, when the IL-1Ra gene was transferred into human synoviocytes using a SCID mouse model, chondrocytemediated chondrolysis of human cartilage was inhibited w30x. The apparent arrest of joint damage associated with a variable and incomplete clinical response, observed in the present study, is entirely consistent with the experimental models.
Cytokine blockade reduces joint in¯ammation in RA w8, 31, 32x. However, IL-1Ra is the ®rst biological agent targeting a cytokine that has demonstrated an effect on progressive joint damage w8x. This study provides some preliminary evidence which may help explain the mechanisms that are critical in this effect.
